Skip to main content
main-content

03-06-2019 | Gastrointestinal cancer | Video

ASCO 2019: Low-dose chemotherapy a valid option for older gastro-oesophageal cancer patients

Peter Hall reports on the GO2 trial that aimed to optimise chemotherapy with oxaliplatin and capecitabine in elderly and frail individuals with advanced gastro-oesophageal cancer (1:40).

Funding for independent interviews at ASCO 2019 was provided in part by F.Hoffmann-La Roche Ltd, Basel, Switzerland

See the research in context now

with trial summaries, expert opinion and congress coverage

Image Credits